Today’s guest is someone who’s seen biotech from both sidesof the table—first as an investor, and now as a builder.

I’m joined by Punit Dhillon, CEO of Skye Bioscience, wherehe’s leading one of the most exciting stories in metabolic health.

Punit started Skye as employee number one and has sincebuilt it into a clinical-stage company with one first-in-class programs and backing from major life science investors like 5AM and Versant. With a background in finance and business development—and a career that includes partnerships with Merck, Genentech, BMS and Pfizer—he brings a unique anddeeply strategic lens to biotech leadership.

In this episode, we dig into the mindset it takes to buildfrom the ground up, the wave of innovation in obesity, and how Skye is carving out its own lane in one of the most competitive markets in biotech.